clonidine has been researched along with Smoking Cessation in 40 studies
Clonidine: An imidazoline sympatholytic agent that stimulates ALPHA-2 ADRENERGIC RECEPTORS and central IMIDAZOLINE RECEPTORS. It is commonly used in the management of HYPERTENSION.
clonidine (amino form) : A clonidine that is 4,5-dihydro-1H-imidazol-2-amine in which one of the amino hydrogens is replaced by a 2,6-dichlorophenyl group.
Smoking Cessation: Discontinuing the habit of SMOKING.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Clonidine was used to reduce withdrawal symptoms of nicotine and increase the success rate of smoking cessation in the smoking cessation clinic of Siriraj Hospital." | 9.08 | Clonidine for smoking cessation. ( Nana, A; Praditsuwan, R, 1998) |
| "Clonidine is probably not effective as a pharmacologic adjunct to behavior modification in smoking cessation." | 9.07 | Randomized, controlled trial of transdermal clonidine for smoking cessation. ( Delcore, MG; Hilleman, DE; Lucas, BD; Mohiuddin, SM, 1993) |
| "This study examines the efficacy of clonidine in smoking cessation and the influence of gender, history of major depression, and measures of nicotine dependence." | 9.07 | Smoking cessation, clonidine, and vulnerability to nicotine among dependent smokers. ( Cooper, TB; Covey, LS; Dalack, GW; Fleiss, J; Glassman, AH; Rivelli, SK; Stetner, F, 1993) |
| "Clonidine in doses of 150 to 450 micrograms per day has been reported to reduce symptoms of craving associated with tobacco withdrawal and, in some cases, to improve long-term abstinence rates of smoking cessation programs." | 9.07 | A placebo-controlled study of three clonidine doses for smoking cessation. ( Forbes, A; Gourlay, S; Kutin, J; Marriner, T; McNeil, J, 1994) |
| "Clonidine may be useful in controlling tobacco withdrawal and in facilitating smoking cessation." | 9.07 | Transdermal clonidine reduced some withdrawal symptoms but did not increase smoking cessation. ( Daughton, DM; Grimm, RH; Heim, C; Nett, L; Petty, TL; Prochazka, AV; Rennard, SI; Sachs, DP; Silvers, GW, 1992) |
| "Based on a small number of trials, in which there are potential sources of bias, clonidine is effective in promoting smoking cessation." | 8.82 | Clonidine for smoking cessation. ( Benowitz, NL; Gourlay, SG; Stead, LF, 2004) |
| "Based on a small number of trials, in which there are potential sources of bias, clonidine is effective in promoting smoking cessation." | 8.80 | Clonidine for smoking cessation. ( Benowitz, NL; Gourlay, SG; Stead, LF, 2000) |
| "Clonidine was used to reduce withdrawal symptoms of nicotine and increase the success rate of smoking cessation in the smoking cessation clinic of Siriraj Hospital." | 5.08 | Clonidine for smoking cessation. ( Nana, A; Praditsuwan, R, 1998) |
| "This study examines the efficacy of clonidine in smoking cessation and the influence of gender, history of major depression, and measures of nicotine dependence." | 5.07 | Smoking cessation, clonidine, and vulnerability to nicotine among dependent smokers. ( Cooper, TB; Covey, LS; Dalack, GW; Fleiss, J; Glassman, AH; Rivelli, SK; Stetner, F, 1993) |
| "Clonidine in doses of 150 to 450 micrograms per day has been reported to reduce symptoms of craving associated with tobacco withdrawal and, in some cases, to improve long-term abstinence rates of smoking cessation programs." | 5.07 | A placebo-controlled study of three clonidine doses for smoking cessation. ( Forbes, A; Gourlay, S; Kutin, J; Marriner, T; McNeil, J, 1994) |
| "Clonidine may be useful in controlling tobacco withdrawal and in facilitating smoking cessation." | 5.07 | Transdermal clonidine reduced some withdrawal symptoms but did not increase smoking cessation. ( Daughton, DM; Grimm, RH; Heim, C; Nett, L; Petty, TL; Prochazka, AV; Rennard, SI; Sachs, DP; Silvers, GW, 1992) |
| " There are now eight effective pharmacotherapies (nicotine gum, patch, nasal spray, inhaler, lozenge/tablet, bupropion, nortriptyline and clonidine) available to aid smoking cessation." | 4.83 | Developments in pharmacotherapy for tobacco dependence: past, present and future. ( Foulds, J; Steinberg, MB; Williams, JM; Ziedonis, DM, 2006) |
| " Medications addressed in this article include (1) first-line agents (nicotine replacement therapy, sustained-release bupropion) that have proven efficacy and are approved by the Food and Drug Administration (FDA) for smoking cessation, (2) second-line agents (nortriptyline, clonidine) that have proven efficacy but no FDA indication for smoking cessation, (3) approaches that use of combination or high-dose therapy, (4) herbal therapies, and (5) emerging therapies that are currently under investigation." | 4.83 | Pharmacologic interventions for smoking cessation. ( Corelli, RL; Hudmon, KS, 2006) |
| " Nortriptyline and clonidine have demonstrated efficacy in aiding smoking cessation, but are regarded as second-line therapies." | 4.82 | Non-nicotine pharmacotherapies for smoking cessation. ( Juniper, Z; Lee, M; McRobbie, H, 2005) |
| "Based on a small number of trials, in which there are potential sources of bias, clonidine is effective in promoting smoking cessation." | 4.80 | Clonidine for smoking cessation. ( Benowitz, NL; Gourlay, SG; Stead, LF, 2000) |
| " Smoking cessation is difficult due to nicotine addiction and withdrawal symptoms." | 3.76 | Current treatment options in smoking cessation. ( Bhat, A; Crain, D, 2010) |
| " There is strong evidence for the efficacy of the atypical antidepressant Bupropion as therapy for smoking cessation." | 3.75 | [Current and future medical drugs for smoking cessation]. ( Deissenrieder, F; Groneberg, D; Kusma, B; Mache, S; Quarcoo, D; Welte, T, 2009) |
| "Cumulative meta-analyses of five smoking cessation interventions (clonidine, nicotine replacement therapy using gum and patch, physician advice and acupuncture) were used to calculate I2 and H." | 3.72 | Evaluating heterogeneity in cumulative meta-analyses. ( Villanueva, EV; Zavarsek, S, 2004) |
| "The clonidine dose was 0." | 2.71 | Twenty-four week maintenance treatment of cigarette smoking with nicotine gum, clonidine and naltrexone. ( Ahmadi, J; Ahmadi, M; Ahmadi, N; Ashkani, H, 2003) |
| "Patients with COPD show higher nicotine dependence and seem to have greater difficulty in quitting smoking." | 2.47 | [Smoking in COPD]. ( Bernabé Barrios, MJ; Rodríguez Hermosa, JL; Santamaría Rodríguez, B; Zamarro García, C, 2011) |
| "Smoking cessation is associated with substantial health benefits." | 2.46 | Pharmacogenetics of smoking cessation therapy. ( Bau, CH; Bizarro, L; Dobler, CJ; Kortmann, GL, 2010) |
| "The outcome of smoking cessation has improved with the availability of proper behavior approaches and medications." | 2.42 | Pharmacotherapy of tobacco dependence. ( Jain, M; Talwar, A; Vijayan, VK, 2004) |
| "Clonidine was the first non-nicotine medication to show efficacy for smoking cessation in multiple studies, but its effect was found to be limited at best." | 2.41 | Advances in non-nicotine pharmacotherapy for smoking cessation. ( Adams, DP; Covey, LS; Glassman, AH; Johnston, JA; Robinson, MD; Sullivan, MA, 2000) |
| " Various dosage forms of nicotine replacement therapy increase smoking quit rates relative to placebo, but they generally do not result in 1-year quit rates of over 20%." | 2.41 | Effect of nonnicotine pharmacotherapy on smoking behavior. ( Golding, M; Hatsukami, DK; Jamerson, BD; Kotlyar, M, 2001) |
| "Nicotine dependence was induced by implanting minipumps that delivered a nicotine solution." | 1.38 | Blockade of CRF1 receptors in the central nucleus of the amygdala attenuates the dysphoria associated with nicotine withdrawal in rats. ( Alexander, JC; Bishnoi, M; Bruijnzeel, AW; Ford, J; Ji, Y; Rogers, JA; Scheick, S, 2012) |
| "Rehabilitation of COPD-patients is an important part of the therapeutic management." | 1.33 | [COPD-rehabilitation]. ( Lichtenschopf, A; Zwick, H, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 12 (30.00) | 18.2507 |
| 2000's | 21 (52.50) | 29.6817 |
| 2010's | 7 (17.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akanbi, MO | 1 |
| Carroll, AJ | 1 |
| Achenbach, C | 1 |
| O'Dwyer, LC | 1 |
| Jordan, N | 1 |
| Hitsman, B | 1 |
| Bilaver, LA | 1 |
| McHugh, MC | 1 |
| Murphy, R | 1 |
| Vasic, N | 1 |
| Kortmann, GL | 1 |
| Dobler, CJ | 1 |
| Bizarro, L | 1 |
| Bau, CH | 1 |
| Kusma, B | 1 |
| Mache, S | 1 |
| Deissenrieder, F | 1 |
| Quarcoo, D | 1 |
| Welte, T | 1 |
| Groneberg, D | 1 |
| Crain, D | 1 |
| Bhat, A | 1 |
| Belcon, AL | 1 |
| Bruijnzeel, AW | 1 |
| Ford, J | 1 |
| Rogers, JA | 1 |
| Scheick, S | 1 |
| Ji, Y | 1 |
| Bishnoi, M | 1 |
| Alexander, JC | 1 |
| Zamarro García, C | 1 |
| Bernabé Barrios, MJ | 1 |
| Santamaría Rodríguez, B | 1 |
| Rodríguez Hermosa, JL | 1 |
| Appel, DW | 1 |
| Aldrich, TK | 1 |
| Ahmadi, J | 1 |
| Ashkani, H | 1 |
| Ahmadi, M | 1 |
| Ahmadi, N | 1 |
| Roddy, E | 1 |
| Villanueva, EV | 1 |
| Zavarsek, S | 1 |
| Gourlay, SG | 3 |
| Stead, LF | 2 |
| Benowitz, NL | 3 |
| Talwar, A | 1 |
| Jain, M | 1 |
| Vijayan, VK | 1 |
| Zwick, H | 1 |
| Lichtenschopf, A | 1 |
| McRobbie, H | 1 |
| Lee, M | 1 |
| Juniper, Z | 1 |
| Schroeder, SA | 1 |
| Foulds, J | 1 |
| Steinberg, MB | 1 |
| Williams, JM | 1 |
| Ziedonis, DM | 1 |
| Corelli, RL | 1 |
| Hudmon, KS | 1 |
| Cofta-Woerpel, L | 2 |
| Wright, KL | 2 |
| Wetter, DW | 2 |
| Sitkauskiene, B | 1 |
| Stravinskaite, K | 1 |
| Sakalauskas, R | 1 |
| Dicpinigaitis, PV | 1 |
| Hill, A | 1 |
| Frishman, WH | 1 |
| Aparici, M | 1 |
| Fernández González, AL | 1 |
| Alegría, E | 1 |
| Hilleman, DE | 1 |
| Mohiuddin, SM | 1 |
| Delcore, MG | 1 |
| Lucas, BD | 1 |
| Glassman, AH | 3 |
| Covey, LS | 3 |
| Dalack, GW | 1 |
| Stetner, F | 2 |
| Rivelli, SK | 1 |
| Fleiss, J | 1 |
| Cooper, TB | 1 |
| Gourlay, S | 1 |
| Forbes, A | 1 |
| Marriner, T | 1 |
| Kutin, J | 1 |
| McNeil, J | 1 |
| Miller, NS | 1 |
| Cocores, JA | 1 |
| Becker, J | 1 |
| Lous, J | 1 |
| Becker, LA | 1 |
| Nana, A | 1 |
| Praditsuwan, R | 1 |
| Sullivan, MA | 1 |
| Johnston, JA | 1 |
| Robinson, MD | 1 |
| Adams, DP | 1 |
| Kotlyar, M | 1 |
| Golding, M | 1 |
| Hatsukami, DK | 1 |
| Jamerson, BD | 1 |
| Prochazka, AV | 1 |
| Petty, TL | 1 |
| Nett, L | 1 |
| Silvers, GW | 1 |
| Sachs, DP | 2 |
| Rennard, SI | 1 |
| Daughton, DM | 1 |
| Grimm, RH | 1 |
| Heim, C | 1 |
| Leischow, SJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II Randomized, Double-Blind Trial of Bupropion Versus Bupropion + Naltrexone for Smoking Cessation[NCT00419731] | Phase 2/Phase 3 | 120 participants (Anticipated) | Interventional | 2006-11-30 | Recruiting | ||
| Effect of Transcranial Direct Current Stimulation (tDCS) on Tobacco Consumption.[NCT01930422] | 34 participants (Actual) | Interventional | 2013-07-31 | Completed | |||
| An Innovative Digital Smoking Cessation Intervention for Low-Income Adults With Substance Use Disorder[NCT04419922] | 100 participants (Actual) | Observational | 2020-04-02 | Active, not recruiting | |||
| Tobacco Treatment Outreach to Reduce Disparities for Primary Care Populations[NCT01156610] | 706 participants (Actual) | Interventional | 2011-11-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
22 reviews available for clonidine and Smoking Cessation
| Article | Year |
|---|---|
The efficacy of smoking cessation interventions in low- and middle-income countries: a systematic review and meta-analysis.
Topics: Adult; Behavior Therapy; Bupropion; Cigarette Smoking; Clonidine; Counseling; Developing Countries; | 2019 |
[Smoking cessation].
Topics: Antidepressive Agents; Clonidine; Combined Modality Therapy; Humans; International Classification of | 2013 |
Pharmacogenetics of smoking cessation therapy.
Topics: Benzazepines; Bupropion; Clonidine; Genome-Wide Association Study; Humans; Nicotine; Nortriptyline; | 2010 |
[Smoking in COPD].
Topics: Benzazepines; Bupropion; Clonidine; Comorbidity; Disease Progression; Europe; Humans; Motivation; Ni | 2011 |
Smoking cessation in the elderly.
Topics: Administration, Cutaneous; Aged; Behavior Therapy; Clonidine; Counseling; Habits; Humans; Nicotine; | 2003 |
Bupropion and other non-nicotine pharmacotherapies.
Topics: Administration, Inhalation; Adrenergic alpha-Agonists; Antidepressive Agents, Second-Generation; Bup | 2004 |
Clonidine for smoking cessation.
Topics: Clonidine; Humans; Randomized Controlled Trials as Topic; Smoking Cessation; Smoking Prevention | 2004 |
Pharmacotherapy of tobacco dependence.
Topics: Adrenergic alpha-Agonists; Adult; Antidepressive Agents, Second-Generation; Bupropion; Clonidine; Fe | 2004 |
Non-nicotine pharmacotherapies for smoking cessation.
Topics: Adrenergic alpha-Agonists; Antidepressive Agents, Tricyclic; Bupropion; Clonidine; Dopamine Uptake I | 2005 |
Developments in pharmacotherapy for tobacco dependence: past, present and future.
Topics: Adolescent; Adult; Bupropion; Clinical Trials as Topic; Clonidine; Drug Administration Routes; Femal | 2006 |
Pharmacologic interventions for smoking cessation.
Topics: Administration, Cutaneous; Administration, Inhalation; Antidepressive Agents, Second-Generation; Ben | 2006 |
Smoking cessation 1: pharmacological treatments.
Topics: Bupropion; Clonidine; Female; Humans; Male; Nicotine; Smoking Cessation | 2006 |
A cost-effectiveness evaluation of single and combined smoking cessation interventions in Texas.
Topics: Adrenergic alpha-Agonists; Antidepressive Agents; Bupropion; Clonidine; Cost-Benefit Analysis; Decis | 2006 |
Smoking cessation 3: multicomponent interventions.
Topics: Behavior Therapy; Bupropion; Clonidine; Combined Modality Therapy; Humans; Motivation; Nicotine; Nor | 2007 |
Smoking cessation pharmacotherapy--nicotine and non-nicotine preparations.
Topics: Administration, Cutaneous; Administration, Inhalation; Benzazepines; Bupropion; Chewing Gum; Clonidi | 2007 |
Nicotine dependence: diagnosis, chemistry, and pharmacologic treatments.
Topics: Acetates; Acetic Acid; Administration, Cutaneous; Adolescent; Chewing Gum; Clonidine; Female; Humans | 1993 |
Is clonidine an effective smoking cessation therapy?
Topics: Adrenergic alpha-Agonists; Clonidine; Drug Interactions; Female; Humans; Male; Meta-Analysis as Topi | 1995 |
[Support and guidelines, nicotine substitutes and clonidine have positive effects on smoking cessation. Five Cochrane meta-analyses on agents used in smoking cessation].
Topics: Adrenergic alpha-Agonists; Clonidine; Counseling; Denmark; Humans; Meta-Analysis as Topic; Nicotine; | 1997 |
Advances in non-nicotine pharmacotherapy for smoking cessation.
Topics: Antidepressive Agents; Bupropion; Buspirone; Clonidine; Humans; Moclobemide; Narcotic Antagonists; S | 2000 |
Clonidine for smoking cessation.
Topics: Clomiphene; Clonidine; Humans; Smoking Cessation; Smoking Prevention | 2000 |
Effect of nonnicotine pharmacotherapy on smoking behavior.
Topics: Amphetamines; Bupropion; Clonidine; Doxepin; Humans; Naltrexone; Nortriptyline; Selective Serotonin | 2001 |
Pharmacologic approaches to smoking cessation.
Topics: Clonidine; Doxepin; Humans; Nicotine; Smoking; Smoking Cessation; Weight Gain | 1991 |
9 trials available for clonidine and Smoking Cessation
| Article | Year |
|---|---|
Twenty-four week maintenance treatment of cigarette smoking with nicotine gum, clonidine and naltrexone.
Topics: Adult; Antihypertensive Agents; Chewing Gum; Clonidine; Double-Blind Method; Humans; Iran; Male; Mid | 2003 |
Changes in cough reflex sensitivity after cessation and resumption of cigarette smoking.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Analgesics, Non-Narcotic; Breath Tests; Caps | 2007 |
[Clonidine in the treatment of tobacco withdrawal. A comparison with nicotine chewing gum].
Topics: Adult; Chewing Gum; Clonidine; Female; Humans; Male; Nicotine; Prospective Studies; Smoking Cessatio | 1994 |
Randomized, controlled trial of transdermal clonidine for smoking cessation.
Topics: Administration, Cutaneous; Adult; Behavior Therapy; Clonidine; Double-Blind Method; Female; Humans; | 1993 |
Smoking cessation, clonidine, and vulnerability to nicotine among dependent smokers.
Topics: Adolescent; Adult; Aged; Clonidine; Depression; Double-Blind Method; Female; Follow-Up Studies; Huma | 1993 |
A placebo-controlled study of three clonidine doses for smoking cessation.
Topics: Adult; Blood Pressure; Clonidine; Dose-Response Relationship, Drug; Double-Blind Method; Drug Admini | 1994 |
Effect of history of alcoholism or major depression on smoking cessation.
Topics: Adult; Alcohol Drinking; Alcoholism; Clonidine; Comorbidity; Depressive Disorder; Female; Follow-Up | 1993 |
Clonidine for smoking cessation.
Topics: Adolescent; Adrenergic alpha-Agonists; Adult; Aged; Aged, 80 and over; Chi-Square Distribution; Clon | 1998 |
Transdermal clonidine reduced some withdrawal symptoms but did not increase smoking cessation.
Topics: Administration, Cutaneous; Adult; Anxiety; Behavior Therapy; Clonidine; Double-Blind Method; Female; | 1992 |
9 other studies available for clonidine and Smoking Cessation
| Article | Year |
|---|---|
[Current and future medical drugs for smoking cessation].
Topics: Adrenergic alpha-Agonists; Antidepressive Agents; Behavior Therapy; Benzazepines; Bupropion; Cannabi | 2009 |
Current treatment options in smoking cessation.
Topics: Adrenergic alpha-Agonists; Antidepressive Agents; Behavior Therapy; Benzazepines; Bupropion; Clonidi | 2010 |
Smoking cessation pharmacotherapy: a concise overview.
Topics: Adrenergic alpha-2 Receptor Agonists; Antidepressive Agents; Benzazepines; Bupropion; Clonidine; Hum | 2011 |
Blockade of CRF1 receptors in the central nucleus of the amygdala attenuates the dysphoria associated with nicotine withdrawal in rats.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-2 Receptor Antagonists; Amygdala; Animals; | 2012 |
[Smoking, nicotine dependence and detoxification therapies].
Topics: Administration, Cutaneous; Administration, Intranasal; Adrenergic alpha-Agonists; Antidepressive Age | 2002 |
Evaluating heterogeneity in cumulative meta-analyses.
Topics: Acupuncture; Clonidine; Counseling; Data Interpretation, Statistical; Effect Modifier, Epidemiologic | 2004 |
[COPD-rehabilitation].
Topics: Acupuncture Therapy; Adrenergic alpha-Agonists; Antidepressive Agents, Second-Generation; Antidepres | 2005 |
What to do with a patient who smokes.
Topics: Antidepressive Agents; Bupropion; Central Nervous System Stimulants; Clonidine; Counseling; Hotlines | 2005 |
What to do with a patient who smokes.
Topics: Antidepressive Agents; Bupropion; Central Nervous System Stimulants; Clonidine; Counseling; Hotlines | 2005 |
What to do with a patient who smokes.
Topics: Antidepressive Agents; Bupropion; Central Nervous System Stimulants; Clonidine; Counseling; Hotlines | 2005 |
What to do with a patient who smokes.
Topics: Antidepressive Agents; Bupropion; Central Nervous System Stimulants; Clonidine; Counseling; Hotlines | 2005 |
Helping patients quit smoking.
Topics: Clonidine; Counseling; Humans; Lobeline; Nicotinic Agonists; Psychotropic Drugs; Randomized Controll | 1998 |